Financial

investors-oncodesign
Corporate
Financial
07/04/2022

Oncodesign confirms its very good results in 2021 and an attractive outlook for 2022

Read the full press release about our very good results in 2021 & an attractive outlook for 2022 for the group & our BUs Service, Biotech & AI.

Nanocyclix portfolio - R&D pipeline
Biotech
Financial
08/02/2022

SEngine Precision Medicine & Oncodesign Announce Collaboration Agreement for the Discovery of New Personalized Cancer Treatment

Read all the details of the collaboration agreement for R&D of a new personalized cancer treatment for aggressive and untreatable tumors.

Financial Result oncodesign
Corporate
Financial
27/01/2022

Oncodesign announces a 2021 turnover of €31.3M, up by 22%, and expects to break even

Find all the 2021 financial information: 2021 turnover of €31.3M, up by 22%, and expects to break even and dive into the BU financial results

Financial Agenda for 2022 - Oncodesign
Corporate
Financial
05/01/2022

ONCODESIGN announces its 2022 financial agenda

Oncodesign announces all the regulatory dates as far as financial information is concerned. Let's have a look :)

Karine Lignel | Senior Executive Vice President - Group Chief Development Officer - Oncodesign
Corporate
Financial
25/10/2021

Oncodesign has appointed Karine Lignel as Group Chief Development Officer

Oncodesign adds a new high-level competence to its COMEX to achieve its external growth objectives with Karine Lignel.

Financial Press Release | Oncodesign
Financial
16/09/2021

Oncodesign announces its results for the first half of 2021

Read all the financial information of Oncodesign and its Business Units Service, Biotech and Artificial Intelligence.

Financial Press Release | Oncodesign
Financial
21/07/2021

Oncodesign announces a sharp increase in turnover in the first half of 2021

Group turnover up by 33% at €15.8M. Despite the global health crisis, which continues to limit international travel...

Corporate
Financial
05/07/2021

Oncodesign announces the appointment of Aline Aubertin as an independent director of the Board of Directors

Oncodesign strenghens its Board by appointing Aline Aubertin as new independent director.

SOLO - Pharmaco-Imaging | Preclinical Imaging Services | Oncodesign
Service
Financial
28/06/2021

Oncodesign launches its new DRIVE-MRT™ service offer in partnership with Covalab, CheMatech and ABX-CRO

[Press Release] Explore our brand new service offer DRIVE-MRT. it allows the rationalization, design and optimization of targeted radiopharmaceutical products that are effective against certain metastatic cancers.

Biotech
Financial
24/06/2021

Oncodesign provides an update on its progress on RIPK2

[Press Release] Find the update of the RIPK2 program and the start of new programs associated with Nanocyclix.

Financial Result oncodesign
Financial
18/06/2021

Oncodesign maintains its revenue and operating income at €38 million in 2020…

[Press Release] Oncodesign maintains its revenue and operating income at €38 million in 2020 and is anticipating an operating profit for the 2nd straight year, within the context of the global public health crisis

A.I
Financial
18/05/2021

InterSystems & Oncodesign partner for the optimization of data use to enhance and accelerate Drug Discovery processes in oncology

Read PRess Release to have an insight on how to organize & leverage healthcare data to accelerate the search for new treatments in oncology using AI.